SEC Form 4 · accession 0001209191-19-004784
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wilhelmus Cm Groenhuysen
Officer — Chief Financial Officer
Period of report
Jan 18, 2019
Accepted (ET)
Jan 22, 2019 · 5:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 18, 2019 | M | 30,000 | $3.44 | A | 67,149 | D | |
| Ordinary SharesF2 | Jan 18, 2019 | S | 30,000 | $45.897 | D | 37,149 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF3 | $3.44 | Jan 18, 2019 | M | 30,000 | D | — | Dec 13, 2021 | Ordinary Shares | 30,000 | 404,663 | D |
Explanation of responses
- F1Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen.
- F2On January 18, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 30,000 shares in multiple trades at prices ranging from $45.85 to $45.92. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F3Options exercised were fully vested as of the date hereof.